Literature DB >> 1749232

Slow-to-recover brain-injured patients: rationale for treatment.

B J Ansell1.   

Abstract

Approximately 10-20% of head injury survivors sustain extensive neurological damage and remain minimally or inconsistently responsive to stimuli for 3-6 months postinjury. These patients, designated as slow to recover (STR), may be candidates for sensory stimulation programs rather than traditional rehabilitation. Medical and insurance personnel have resisted referral and payment for treatment because of the lack of objective measures of progress, a theoretical basis for treatment, and evidence of treatment efficacy. A valid, reliable assessment tool has recently been developed (Western Neuro Sensory Stimulation Profile) that assesses low-level cognitive/communicative function and documents improvement in STR patients. This article addresses the theoretical rationale for treatment. Evidence from four areas--sensory deprivation, enriched environments, nervous system plasticity, and sensitive periods of neurodevelopment--suggests that sensory stimulation programs are potentially beneficial for STR patients. Speech-language pathologists are encouraged to study the recovery patterns of STR patients and to determine the efficacy of treatment strategies.

Entities:  

Mesh:

Year:  1991        PMID: 1749232     DOI: 10.1044/jshr.3405.1017

Source DB:  PubMed          Journal:  J Speech Hear Res        ISSN: 0022-4685


  2 in total

1.  Improving motor and cognitive recovery following severe traumatic brain injury using advanced emotional audio-video stimulation: Lessons from a case report.

Authors:  Rosaria De Luca; Patrizia Pollicino; Carmela Rifici; Cristina de Cola; Luana Billeri; Silvia Marino; Simona Trifirò; Elisabeth Fiumara; Maria Randazzo; Placido Bramanti; Michele Torrisi
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

2.  Changes in responsiveness when brain injury survivors with impaired consciousness hear different voices.

Authors:  Steffany Chleboun; Karen Hux; Jeff Snell
Journal:  Brain Inj       Date:  2009-02       Impact factor: 2.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.